Product Description: Wedica is a once-weekly dipeptidyl peptidase-IV (DPP-4) inhibitor. It controls blood glucose levels by selectively and continually inhibiting DPP-4, an enzyme that causes the inactivation of glucagon-like peptide-1 and glucagon-dependent insulinotropic polypeptide, incretin hormones* that play an important role in blood glucose regulation. The inhibition of DPP-4 increases insulin secretion depending on blood glucose concentration, thereby controlling blood glucose levels. Wedica is available in tablet form for oral administration.   Product Features:

• Once Weekly Dose.
• Lesser hypoglycemic events.
• 4 and 12-fold more potent than Alogliptin and Sitagliptin.